inTest Q3 Results: Sales guidance misses analyst estimates

1 min read | Published on 10 Aug 2026, 04:11 PM |Updated on 10 Aug 2026, 04:11 PM

Reviewed by

Ashish TScanX News Team

Key Highlights

inTest projects Q3 sales of $33.000M-$35.000M, missing the $35.068M analyst estimate. The guidance highlights a revenue shortfall against consensus expectations for the quarter.

*this image is generated using AI for illustrative purposes only.

inTest (AMEX: INTT) has projected third-quarter sales to range between $33.000 million and $35.000 million, falling below the $35.068 million estimate set by analysts. The guidance indicates that the company’s revenue performance for the quarter is likely to underperform market expectations, with the upper bound of the forecast still trailing the consensus figure by approximately $68,000.

The company released these figures as part of its standard quarterly outlook disclosure. The guidance provides investors with an early indication of operational performance before the official financial results are filed. No specific reasons for the variance from estimates were provided in the initial announcement.

Guidance vs. Estimates

The following table compares inTest’s projected sales range against the prevailing analyst consensus:

Metric	inTest Guidance	Analyst Estimate
Q3 Sales	$33.000M – $35.000M	$35.068M

What the Numbers Show

The gap between the upper end of inTest’s guidance and the analyst estimate suggests a conservative outlook for the quarter. While the lower bound of $33.000 million represents a more significant deviation, even the most optimistic scenario within the company’s own projection fails to meet the $35.068 million benchmark. Investors will need to monitor subsequent filings for details on the specific drivers behind this shortfall, such as demand fluctuations or pricing pressures.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Will inTest adjust its full-year revenue guidance to reflect the Q3 shortfall, and if so, by what margin?

Which specific end-markets or product segments are driving the demand weakness indicated by the lower sales projection?

How might this miss impact inTest's gross margins given potential fixed cost absorption issues at lower revenue levels?

inTest Q2 Results: Sales guidance raised to $35.000M vs $33.013M est

0 min read | Published on 31 Jul 2026, 06:22 PM |Updated on 31 Jul 2026, 06:22 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

inTest upgrades Q2 preliminary sales guidance to $35.000 million, beating the $32.000 million-$34.000 million range and $33.013 million estimate. The revision highlights strong operational performance ahead of final results.

*this image is generated using AI for illustrative purposes only.

inTest (AMEX: INTT) has raised its preliminary sales guidance for the second quarter to $35.000 million, exceeding market expectations of $33.013 million. This upward revision signals stronger-than-anticipated demand or operational performance during the period, as the new figure sits above the company’s prior guidance range of $32.000 million to $34.000 million.

The adjustment reflects a positive deviation from both internal forecasts and external analyst consensus. By lifting the top end of its previous range by $1.000 million, inTest indicates robust underlying business momentum heading into the finalization of its quarterly results.

Guidance Revision Details

The following table outlines the changes in inTest’s sales outlook:

Metric	Value
Previous Guidance Range	$32.000 million - $34.000 million
Analyst Estimate	$33.013 million
Revised Preliminary Sales	$35.000 million

What the Numbers Show

The revision represents a clear beat against consensus estimates. With the revised figure of $35.000 million, inTest is now projecting sales approximately $1.987 million higher than the estimated $33.013 million. This suggests that operational execution has outpaced initial projections, potentially driven by stronger order intake or accelerated revenue recognition during the quarter.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Which specific product lines or geographic regions are driving the unexpected surge in Q2 demand for inTest?

Will inTest raise its full-year revenue guidance to reflect this stronger-than-anticipated Q2 performance?

How might this beat against consensus estimates impact inTest's stock valuation and short-term trading volume?